Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

Flexible manufacturing OEM & ODM factory Taiwan

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Graphene insole manufacturing factory in Taiwan

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.Custom foam pillow OEM in Taiwan

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Taiwan foot care insole ODM expert

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Taiwan OEM factory for footwear and bedding solutions

Researchers from Brigham and Women’s Hospital and Harvard Medical School found that humans tend to produce antibodies that target the same viral regions repeatedly, called “public epitopes.” Using a tool called VirScan, the team analyzed blood samples from the U.S., Peru, and France, and discovered 376 commonly targeted epitopes. These public epitopes allow viruses to mutate a single amino acid and reinfect previously immune populations. The findings have significant implications for understanding immunity, predicting immune responses, and developing therapies and vaccines. Using a tool called VirScan, Brigham investigators found that people produced shared antibody responses to certain regions of the virus, likely leading to selective pressure and new variants that can repeatedly escape detection by prior immunity. The human body is capable of creating a vast, diverse repertoire of antibodies—the Y-shaped sniffer dogs of the immune system that can find and flag foreign invaders. Despite our ability to create a range of antibodies to target viruses, humans create antibodies that target the same viral regions again and again, according to a new study led by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, and Harvard Medical School. These “public epitopes” mean that the generation of new antibodies is far from random and that a virus may be able to mutate a single amino acid to reinfect a population of previously immune hosts. The team’s findings, which have implications for our understanding of immunity and public health, will be published today (April 6) in the journal Science. “Our research may help explain a lot of the patterns we’ve seen during the COVID-19 pandemic, especially in terms of re-infection,” said corresponding author Stephen J. Elledge, PhD, the Gregor Mendel Professor of Genetics at the Brigham and HMS. “Our findings could help inform immune predictions and may change the way people think about immune strategies.” Alignment of multiple antibodies that use a lysine-specific GRAB motif shows that they recognize their targets in very similar ways. Credit: Stephen J. Elledge, PhD, and Ellen L. Shrock, PhD. Before the team’s study, there were hints, but no clear evidence, that people’s immune systems didn’t target sites on a viral protein at random. In isolated examples, investigators had seen recurrent antibody responses across individuals—people recreating antibodies to home in on the same viral protein location (known as an epitope). But the study by Elledge and colleagues helps explain the extent and underlying mechanisms of this phenomenon. Insights from VirScan Analysis The team used a tool the Elledge lab developed in 2015 called VirScan, which can detect thousands of viral epitopes — sites on viruses that antibodies recognize and bind to — and give a snapshot of a person’s immunological history from a single drop of blood. For the new study, the researchers used VirScan to analyze 569 blood samples from participants in the U.S., Peru, and France. They found that recognition of public epitopes — viral regions recurrently targeted by antibodies — was a general feature of the human antibody response. The team mapped 376 of these commonly targeted epitopes, uncovering exactly where antibodies bind their targets. The team found that antibodies recognized public epitopes through germline-encoded amino acid binding (GRAB) motifs—regions of the antibodies that are particularly good at picking out one specific amino acid. So, instead of randomly choosing a target, human antibodies tend to focus on regions where these amino acids are available for binding, and thus repeatedly bind the same spots. A small number of mutations can help a virus avoid detection by these shared antibodies, allowing the virus to reinfect populations that were previously immune. “We find an underlying architecture in the immune system that causes people, no matter where in the world they live, to make essentially the same antibodies that give the virus a very small number of targets to evade in order to reinfect people and continue to expand and further evolve,” said lead author Ellen L. Shrock, PhD, of the Elledge lab. Immune Strategies and Treatments Interestingly, the team notes that nonhuman species produce antibodies that recognize different public epitopes from those that humans recognize. And, while it is more likely for a person to produce antibodies against a public epitope, some people do produce rarer antibodies, which may more effectively protect them from reinfection. These insights could have important implications for treatments developed against COVID-19, such as monoclonal antibodies, as well as for vaccine design. “The more unique antibodies may be a lot harder to evade, which is important to consider as we think about the design of better therapies and vaccines,” said Elledge. Reference: “Germline-encoded amino acid–binding motifs drive immunodominant public antibody responses” by Ellen L. Shrock, Richard T. Timms, Tomasz Kula, Elijah L. Mena, Anthony P. WestJr, Rui Guo, I-Hsiu Lee, Alexander A. Cohen, Lindsay G. A. McKay, Caihong Bi, Keerti, Yumei Leng, Eric Fujimura, Felix Horns, Mamie Li, Duane R. Wesemann, Anthony Griffiths, Benjamin E. Gewurz, Pamela J. Bjorkman and Stephen J. Elledge, 7 April 2023, Science. DOI: 10.1126/science.adc9498 Funding: This research was supported by the SARS-CoV-2 Viral Variants Program and the Value of Vaccine Research Network, the MassCPR, the National Institutes of Health (1P01AI165072, K99DE031016, AI139538, AI169619, AI170715, and AI170580),  the National Science Foundation (Graduate Research Fellows Program), Pemberton-Trinity Fellowship, Sir Henry Wellcome Fellowship (201387/Z/16/Z), Jane Coffin Childs Postdoctoral Fellowship, Burroughs Wellcome Career Award in Medical Sciences. Elledge is an Investigator with the Howard Hughes Medical Institute. Disclosures: Elledge and co-author Tomasz Kula are founders of TSCAN Therapeutics and ImmuneID. Elledge is a founder of MAZE Therapeutics and Mirimus, and serves on the scientific advisory board of Homology Medicines, TSCAN Therapeutics, MAZE Therapeutics, none of which impact this work. Shrock was a consultant for ImmuneID. Elledge and Kula are inventors on a patent application filed by the Brigham and Women’s Hospital (US20160320406A) that covers the use of the VirScan library to identify pathogen antibodies in blood.

Scientists developed a revolutionary organoid model of the dopaminergic system, providing significant insights into Parkinson’s disease and the long-lasting effects of cocaine on the brain. This model is a promising tool for advancing Parkinson’s disease treatments and understanding the enduring impact of drug addiction. Credit: SciTechDaily.com Breakthrough organoid model replicates essential neural network. A new organoid model of the dopaminergic system sheds light on its intricate functionality and potential implications for Parkinson’s disease. The model, developed by the group of Jürgen Knoblich at the Institute of Molecular Biotechnology (IMBA) of the Austrian Academy of Sciences, replicates the dopaminergic system’s structure, connectivity, and functionality. The study, published on December 5 in Nature Methods, also uncovers the enduring effects of chronic cocaine exposure on the dopaminergic circuit, even after withdrawal. Dopamine’s Role in Reward and Motor Control A completed run, the early morning hit of caffeine, the smell of cookies in the oven — these rewarding moments are all due to a hit of the neurotransmitter dopamine, released by neurons in a neural network in our brain, called the “dopaminergic reward pathway.” Apart from mediating the feeling of “reward,” dopaminergic neurons also play a crucial role in fine motor control, which is lost in diseases such as Parkinson’s disease. Despite dopamine’s importance, key features of the system are not yet understood, and no cure for Parkinson’s disease exists. In their new study, the group of Jürgen Knoblich at IMBA developed an organoid model of the dopaminergic system, which not only recapitulates the system’s morphology and nerve projections, but also its functionality. Dopaminergic neurons in the ventral midbrain (red) and ventral midbrain projections into striatal and cortical tissue (green). Credit: (c) Daniel Reumann/IMBA Understanding Parkinson’s Disease Through the Model Tremor and a loss of motor control are characteristic symptoms of Parkinson’s disease and are due to a loss of neurons that release the neurotransmitter dopamine, called dopaminergic neurons. When dopaminergic neurons die, fine motor control is lost and patients develop tremors and uncontrollable movements. Although the loss of dopaminergic neurons is crucial in the development of Parkinson’s disease, the mechanisms how this happens, and how we can prevent – or even repair – the dopaminergic system is not yet understood. Animal models for Parkinson’s disease have provided some insight into Parkinson’s disease, however as rodents do not naturally develop Parkinson’s disease, animal studies proved unsatisfactory in recapitulating hallmark features of the disease. In addition, the human brain contains many more dopaminergic neurons, which also wire up differently within the human brain, sending projections to the striatum and the cortex. “We sought to develop an in vitro model that recapitulates these human features in so-called brain organoids,” explains Daniel Reumann, previously a PhD student in the lab of Jürgen Knoblich at IMBA, and first author of the paper. “Brain organoids are human stem cell-derived three-dimensional structures, which can be used to understand both human brain development, as well as function,” he explains further. Developing and Testing the Organoid Model The team first developed organoid models of the so-called ventral midbrain, striatum, and cortex – the regions linked by neurons in the dopaminergic system – and then developed a method for fusing these organoids together. As happens in the human brain, the dopaminergic neurons of the midbrain organoid send out projections to the striatum and the cortex organoids. “Somewhat surprisingly, we observed a high level of dopaminergic innervation, as well as synapses forming between dopaminergic neurons and neurons in striatum and cortex,” Reumann recalls. To assess whether these neurons and synapses are functional, the team collaborated with Cedric Bardy’s group at SAHMRI and Flinders University, Australia, to investigate if neurons in this system would start to form functional neural networks. And indeed, when the researchers stimulated the midbrain which contains dopaminergic neurons, neurons in the striatum and cortex responded to the stimulation. “We successfully modelled the dopaminergic circuit in vitro, as the cells not only wire correctly, but also function together,” Reumann sums up. Potential Applications in Parkinson’s Disease Therapy The organoid model of the dopaminergic system could be used to improve cell therapies for Parkinson’s disease. In first clinical studies, researchers have injected precursors of dopaminergic neurons into the striatum, to try and make up for the lost natural innervation. However, these studies have had mixed success. In collaboration with the lab of Malin Parmar at Lund University, Sweden, the team demonstrated that dopaminergic progenitor cells injected into the dopaminergic organoid model mature into neurons and extend neuronal projections within the organoid. “Our organoid system could serve as a platform to test conditions for cell therapies, allowing us to observe how precursor cells behave in a three-dimensional human environment,” Jürgen Knoblich, the study’s corresponding author, explains. “This allows researchers to study how progenitors can be differentiated more efficiently and provides a platform which allows to study how to recruit dopaminergic axons to target regions, all in a high-throughput manner.” Insights Into the Reward System Dopaminergic neurons also fire whenever we feel rewarded, thus forming the basis of the “reward pathway” in our brains. But what happens when dopaminergic signaling is perturbed, such as in addiction? To investigate this question, the researchers made use of a well-known dopamine reuptake inhibitor, cocaine. When the organoids were exposed to cocaine chronically, over 80 days, the dopaminergic circuit changed functionally, morphologically and transcriptionally. These changes persisted, even when cocaine exposure was stopped 25 days before the end of the experiment, which simulated the withdrawal condition. “Even after almost a month after stopping cocaine exposure, the effects of cocaine on the dopaminergic circuit were still visible, which means that we can now investigate what the long-term effects of dopaminergic overstimulation are in a human-specific in vitro system,” Reumann Reference: “In vitro modeling of the human dopaminergic system using spatially arranged ventral midbrain–striatum–cortex assembloids” by Daniel Reumann, Christian Krauditsch, Maria Novatchkova, Edoardo Sozzi, Sakurako Nagumo Wong, Michael Zabolocki, Marthe Priouret, Balint Doleschall, Kaja I. Ritzau-Reid, Marielle Piber, Ilaria Morassut, Charles Fieseler, Alessandro Fiorenzano, Molly M. Stevens, Manuel Zimmer, Cedric Bardy, Malin Parmar and Jürgen A. Knoblich, 5 December 2023, Nature Methods. DOI: 10.1038/s41592-023-02080-x Funding: Austrian Academy of Sciences, Austrian Federal Ministry of Education, Science and Research, City of Vienna, H2020 European Research Council, Austrian Science Fund, Austrian Lotteries, New York Stem Cell Foundation, H2020 European Research Council, Swedish Research Council, Rosetrees Trust, UK Regenerative Medicine Platform Hub, Michael J. Fox Foundation for Parkinson’s Research, Hospital Research Foundation, Shake it up Foundation, Neurosurgical Research Foundation, Australian Research Council

Coronin 1 promotes long-term survival of the T cells of our immune system. Credit: Nano Imaging Lab SNI/Biozentrum, University of Basel They are at the forefront in the fight against viruses, bacteria, and malignant cells: the T cells of our immune system. But the older we get, the fewer of them our body produces. Thus, how long we remain healthy also depends on how long the T cells survive. Researchers at the University of Basel have now uncovered a previously unknown signaling pathway essential for T cell viability. Like human beings, every cell in our body tries to ward off death as long as it can. This is particular true for a specific type of immune cells, called T-lymphocytes, or T cells for short. These cells keep viruses, bacteria, parasites and cancerous cells at bay. While T cell production is an active process in infants, children and young adults, it comes to a gradual stop upon aging, meaning that in order to maintain adequate immunity up to an old age, your T cells should better live as long as you. How T cells manage to survive for such a long time, up to several decades in humans, has long remained unclear. In collaboration with scientists at the Department of Biomedicine and sciCORE, the Center for Scientific Computing of the University of Basel, Professor Jean Pieters’ research group at the Biozentrum has now revealed the existence of a hitherto unrecognized pathway promoting long-term survival of T cells. In Science Signaling they report that this signaling pathway, regulated by the protein coronin 1, is responsible for suppressing T cell death. Coronin 1 enables long-term survival In earlier research, Pieters’ team and others had shown that coronin 1 is essential for the survival of peripheral T cells while being dispensable for their production and maturation. In their current study, the team has now been able to show that pathways previously thought to be implicated in T cell survival were in fact independent of coronin 1, and they furthermore uncovered a unknown coronin 1-driven signaling pathway that regulates T cell survival. To hunt down this coronin 1-dependent pathway, the researchers established a procedure to collect highly pure T cells and subsequently analyzed the whole set of RNA molecules in normal and coronin 1-deficient T cells. “Somewhat unexpectedly, in-depth bioinformatic analysis of the many gigabytes of data did not reveal any difference between these two groups of T cells. That’s when the COVID-19-induced lock down came in,” says Pieters, the lead author. “So, I decided to use the home-office time to sift through the many tables and lists of genes to see if there were any correlations with known signaling pathways whose deregulation could explain the disappearance of T cells upon coronin 1 depletion.” Researchers reveal unrecognized pathway Strikingly, there was a positive match linking coronin 1-dependent T cell survival to a pathway involving the modification of the plasma membrane composition by the lipid kinase PI3Kdelta. Together with PI3K expert Professor Matthias Wyman at the Department of Biomedicine, the researchers were able to put together the pieces of the puzzle, leading to their realization that coronin 1 maintains PI3Kdelta activity and, in this way, suppresses T cell death. “It will now be exciting to follow up on these findings, not only to understand the role of other members of the coronin protein family in cell survival, but also how cell populations, such as circulating T cells in blood, are being maintained long-term,” says Pieters. Finally, given the importance of T cells for regulating processes as diverse as viral and microbial pathogen resistance, tumorigenicity, and autoimmunity, this work may contribute to a better control of both appropriate as well as undesirable T cell activities. Reference: “Suppression of caspase 8 activity by a coronin 1–PI3Kδ pathway promotes T cell survival independently of TCR and IL-7 signaling” by Mayumi Mori, Julie Ruer-Laventie, Wandrille Duchemin, Philippe Demougin, Tohnyui Ndinyanka Fabrice, Matthias P. Wymann and Jean Pieters, 21 December 2021, Science Signaling. DOI: 10.1126/scisignal.abj0057

DVDV1551RTWW78V